Ep. 252, Chapter 3: Global Expansion Of RNAi with Tolga Tanguler

22:57 – 34:07

Alnylam Pharmaceuticals has expanded its footprint to more than 60 markets, with nearly half of its revenue generated outside the U.S. —diversifying the company’s revenue and enabling it to capitalize on region-specific opportunities. Tanguler explains why Alnylam’s commercialization approach involves categorizing markets by archetype (e.g., developed vs. distributor-led) rather than strict geography. He also speaks about how the company decides between direct presence and distribution partners, as well as the principles that guide Alnylam’s pricing strategy to maximize patient access.